Do older patients get higher liver-enzyme changes from tigecycline?
The provided information does not include study results or labeling data that compare tigecycline’s effect on liver enzymes in elderly versus non-elderly patients. Without those details, it is not possible to say whether the impact is more pronounced in older adults.
What does tigecycline do to liver enzymes in general?
No specific data on tigecycline-associated liver-enzyme elevations (such as ALT/AST) in either the general population or by age are included in the provided material. So there’s not enough context to describe the pattern or magnitude of enzyme changes.
Could age change risk because of liver function or dosing?
Tigecycline exposure and tolerability can be influenced by factors like baseline liver function, overall health, and pharmacokinetics, which often differ with age. However, the question asks specifically whether the impact is more pronounced in the elderly, and the necessary age-stratified evidence is not present here.
What to check for a reliable answer
To determine whether the effect is more pronounced in the elderly, the most relevant sources would be:
- Tigecycline prescribing information (sections on hepatic impairment and adverse reactions), especially any age subgroup analyses.
- Clinical trial safety tables that report ALT/AST (or “transaminase elevations”) by age group.
If you share the tigecycline label text or the study (or a link), I can extract whether liver-enzyme elevations are reported as higher in elderly patients and quantify the difference.
Sources
No sources were provided in the prompt.